Pseudovirus News and Research

RSS

Biochemical and structural evidence demonstrates Omicron mutations are better adapted to mouse ACE2 than to human ACE2

Researchers demonstrated the structural basis of how the receptor-binding domain nested Omicron mutations have adapted to mouse angiotensin-converting enzyme 2 rather than human ACE2.

22 Oct 2022

Study suggests an immunological benefit of combining previous natural infection with vaccination against COVID-19 using a combination of different vaccine platforms

Researchers explored SARS-CoV-2-targeted immune responses among COVAC1 participants who received a novel saRNA vaccine followed by the mRNA BNT162b2 vaccine BNT162b2 vaccine, with or without prior COVID-19 history.

7 Oct 2022

$The immune responses and safety of fractional third-doses of heterologous COVID-19 vaccines after CoronaVac primary series$

The immune responses and safety of fractional third-doses of heterologous COVID-19 vaccines after CoronaVac primary series

Researchers evaluated the vaccine effectiveness of half-doses of AZD1222 or BNT162b2 COVID-19 vaccines as a booster dose following primary series vaccination with CoronaVac.

6 Oct 2022

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

Study suggests B-cell responses to booster vaccines are impeded by recent SARS-CoV-2 infection

Researchers investigated whether the time of booster vaccination relative to SARS-CoV-2 infection is a crucial determinant of the elicited immune response; in particular, the antibody and B-cell responses.

29 Sep 2022

Significant humoral immune evasion contributes to the emergence and rapid spread of Arg346-mutated BA.4 and BA.5 sublineages

=Researchers measured the neutralizing titers of plasma samples against the SARS-CoV-2 new variant of concern Omicron's sub-variants BA.4 and BA.5 with arginine (Arg)346 mutations.

29 Sep 2022

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Researchers comparatively evaluated antibody responses against SARS-CoV-2 among immunodeficient individuals pre- and post-intravenous immunoglobulin product infusions.

27 Sep 2022

First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine

In a recent study posted to the bioRxiv* preprint server, researchers from Germany and the United States analyzed the association between exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/BA.5 spike glycoprotein and pan-Omicron neutralization.

27 Sep 2022

Omicron BA.1 breakthrough infection in vaccinated individuals recall memory B cells to confer immunity

In a new study, researchers followed up with individuals vaccinated with a COVID-19 vaccine based on the mRNA platform up to six months following Omicron BA.1 breakthrough infection to trace the evolution of their antibody immunity.

26 Sep 2022

A fast and powerful method for the production of SARS-CoV-2 virus-like particles in insect cells

Researchers presented the direct plasmid transfection method for SARS-CoV-2 virus-like particle production in insect cells and applied the VLPs to evaluate the efficacy of monoclonal antibodies and vaccinated donor sera.

26 Sep 2022

Does BA.2 breakthrough infection shift cross-neutralization activity towards the BA.4 and BA.5 Omicron sublineages?

Researchers investigated the SARS-CoV-2 VOC Omicron's immune escape mechanisms.

22 Sep 2022

Study reveals improved immunogenicity and safety of bivalent Omicron-containing mRNA-1273.214 candidate booster vaccine

In a new study, a team of researchers assessed the safety and efficacy of a bivalent candidate vaccine containing spike messenger ribonucleic acids of the ancestral Wuhan-Hu-1 strain and the Omicron B.1.1.529 [BA.1] variant of SARS-CoV-2.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

Discovery of antibodies that may eliminate the need for COVID vaccines

...

11 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

Omicron BA.2.75 not more resistant to antibodies than the currently dominating BA.5 variant, study suggests

In a recent study, researchers from Karolinska Institutet in Sweden, and others, have characterised the new omicron variant BA.2.75, comparing its ability to evade antibodies against current and previous variants.

2 Sep 2022

What are the effects of e-cigarettes and their constituents on SARS-CoV-2 infection?

In a new study, researchers evaluated whether e-cigarette (EC) aerosols promoted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

29 Aug 2022

Durability of immune protection after booster immunization with COVID-19 adjuvanted subunit vaccine against the immune-evasive Omicron BA.1 variant

Researchers explored the durability of immunity imparted by the SARS-CoV-2 adjuvanted subunit vaccine against the Omicron variant.

22 Aug 2022

Impact of SARS-CoV-2 Omicron subvariant breakthrough infections on memory responses

Researchers examined antibodies (Abs) generated by memory B cells (MBCs) after three and four SARS-CoV-2 exposures by infections with SARS-CoV-2 Delta and Omicron BA.1 variants, respectively.

16 Aug 2022

Mechanistic insights into engineered ACE2 receptor traps

Researchers determined the cryo-electron microscopic (cryo-EM) structures of engineered angiotensin-converting enzyme 2 (ACE2) receptor traps.

12 Aug 2022